Business
Patent Issues on ARIUS Lead Antibody
Patent Issues on ARIUS Lead Antibody.
About this update from Affinity Metals Corp
[{"type":"text","content":"\n\n\n\n\nTSX Venture Exchange: ARI\n\nTORONTO, March 9 /CNW/ - ARIUS Research Inc. (TSX-VE: ARI) announced\ntoday that it has received notice from the United States Patent and Trademark\nOffice that U.S. patent No. 7,009,040 was issued on March 7, 2006 for ARIUS'\nlead anti-CD63 antibody, AR7BD-33-11A. Previously ARIUS announced that it had\nreceived a Notice of Allowance in October 2005.\nThe patent covers the antibody molecule, various uses of the antibody,\nits derivatives, and a method for using it, and other similar antibodies, to\ntreat cancers such as prostate and breast cancer. ARIUS has several additional\npatent applications pending that will continue to enhance the value of this\nand other important antibody assets.\nAR7BD-33-11A is one of a series of anti-CD63 antibodies generated through\nARIUS' proprietary FunctionFIRST(TM) product platform. ARIUS has shown that\nantibodies directed against the CD63 target have a significant impact on\ncancers such as human pancreatic cancer, melanoma, breast and prostate\ncancers. Due to its potency, and other desirable characteristics, AR7BD-33-11A\nwas selected as a lead antibody and humanized to make it suitable for human\nclinical trials.\n\"Patents are key to ARIUS' commercial success,\" commented Dr. David S.\nYoung, President and Chief Scientific Officer of ARIUS, \"Issued patents also\nhelp validate our technology and demonstrate the inventiveness of our\nscience.\"\n\nAbout ARIUS Research\n\nARIUS Research Inc. is a biotechnology company dedicated to personalizing\ncancer therapy through the discovery and development of novel anticancer\nmonoclonal antibodies (MAbs). Established in 1999, ARIUS has built a\nproprietary technology platform, FunctionFIRST(TM), that rapidly identifies\npowerful MAbs targeting a variety of cancer indications. This antibody\ngeneration engine has enabled ARIUS to assemble a growing pipeline, which is\nused for commercial collaborations and in-house development. ARIUS has ongoing\npartnerships with key biotechnology and drug development companies. The\ncompany is listed on the TSX Venture Exchange under the symbol \"ARI\".\n\nForward-Looking Statement\n\nCertain statements in this news release constitute \"forward-looking\nstatements\" within the meaning of the Private Securities Litigation Reform Act\nof 1995, which involve known and unknown r...